3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
123
Recurrence
12
Neoplasms
8
Immunoglobulin Light-chain Amyloidosis
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
5
Smoldering Multiple Myeloma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Plasmacytoma
2
Plasmablastic Lymphoma
2
Neoplasm, Residual
2
Myelodysplastic Syndromes
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Amyloidosis
2
Acute Kidney Injury
2
Triple Negative Breast Neoplasms
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Temozolomide
100
Radiotherapy
49
Magnetic Resonance Spectroscopy
38
Radiation
28
Specimen Handling
25
pembrolizumab
22
Bevacizumab
22
Lomustine
16
Nivolumab
14
Surgical Procedures, Operative
10
atezolizumab
8
Cyclophosphamide
8
Biopsy
8
abemaciclib
7
Ipilimumab
7
fludarabine
6
Radiotherapy, Intensity-Modulated
6
Carboplatin
6
Aminolevulinic Acid
6
olaparib
5
Metformin
5
Drug Therapy
5
Diet, Ketogenic
5
Dianhydrogalactitol
5
poly ICLC
4
cemiplimab
4
Radiosurgery
4
Photons
4
Leukapheresis
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
daratumumab
×
1 year
×
Clear all
NCT04922723
2026-04-28
PRIDE
West Virginia University
Phase 1/2
Active not recruiting
16 enrolled